State of the Art – Has the time come to introduce early detection of prostate cancer?
NICE and SMC approve Darolutamide to revolutionise the treatment of progressing prostate cancer
The National Institute for Clinical Excellence (NICE) and the Scottish medicines Commission (SMC) have both now approved the use of a new drug, Darolutamide, as an option for treating hormone-relapsed prostate cancer in adults at high risk of developing metastatic disease. This stage of the disease is variably described as: Non-metastatic castrate resistant prostate cancer […]
Tackle demands protection for people with prostate cancer after millions have been abandoned
Tackle has joined forces with other leading cancer charities eg Cancer Research UK and Macmillan Cancer Support to write to the Prime Minister and the other heads of regional parliaments to demand protection for men with prostate cancer to ensure that diagnosis, treatment and clinical trials will not continue to be delayed by COVID-19. The […]
NICE approve Darolutamide to revolutionise the treatment of progressing prostate cancer
The National Institute for Clinical Excellence (NICE) has just approved the use of a new drug, Darolutamide, as an option for treating hormone-relapsed prostate cancer in adults at high risk of developing metastatic disease. This stage of the disease is variably described as: Non-metastatic castrate resistant prostate cancer Non-metastatic hormone resistant prostate cancer Non-metastatic hormone […]
Tackle Prostate Cancer Appoints Sarah Gray as National Support & Development Manager
Tackle Prostate Cancer charity, the voice of prostate cancer patients and their families in the UK is delighted to announce the appointment of Sarah Gray as its new National Support and Development Manager. The charity has been awarded funding by the National Lottery for the project Tackling Prostate Cancer – peer-to-peer support for men with prostate […]
Appeal application against NICE decision accepted
Steve Allen, Tackle Patient Representative, reports that the combined application for appeal against the NICE decision on Abiraterone made by Tackle and Prostate Cancer UK has been successful. A submission made by Prof Nick James, a nominated clinical expert, has also been accepted. This is merely a first step in a long process. It does […]
NICE rejects use of Abiraterone for men with newly-diagnosed metastatic prostate cancer
Tackle is extremely disappointed to report the latest decision by the National Institute for Health and Care Excellence (NICE) to reject the use of Abiraterone for men with newly-diagnosed metastatic prostate cancer in England and Wales. Current first-line treatment for men with newly-diagnosed metastatic hormone sensitive prostate cancer (ndmhsPCa) is hormone therapy with additional chemotherapy (Docetaxel). […]
Restarting Cancer Services in the NHS after COVID-19
COVID-19 is an unprecedented crisis which has had a profound impact on health and care services across the UK and will continue to have an impact for the months and years to come. To guide the restoration of services, Tackle Prostate Cancer along with 24 other cancer charities have come together – as One Cancer Voice – to develop […]
European Experts Back Prostate Cancer Screening
Tackle are at the forefront of the campaign for a targeted national screening programme for prostate cancer. Prostate cancer is now the most commonly diagnosed cancer in UK and the annual toll of deaths from prostate cancer continues to rise, now topping 12,000, with deaths exceeding those from breast cancer. The European Association of Urology have now […]
Tackle Trustee Roshani Perera turns the spotlight on mental health in cancer care
Tackle Trustee Roshani Perera, director of the Wicked Minds healthcare consultancy, has written an article that has been published in PharmaTimes. The article looks at the provision of psychological support services for men living with prostate cancer and their carers and families across England based on a Tackle Freedom of Information request. Click here to read the article […]